Show simple item record

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

dc.contributor.authorBroadhurst, Helen
dc.contributor.authorAntonia, Scott J.
dc.contributor.authorVillegas, Augusto
dc.contributor.authorVicente, David
dc.contributor.authorHui, Rina
dc.contributor.authorPaz-Ares, Luis
dc.contributor.authorMurakami, Shuji
dc.contributor.authorWadsworth, Catherine
dc.contributor.authorDennis, Phillip A.
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorSpigel, David R.
dc.contributor.authorSenan, Suresh
dc.contributor.authorLanger, Corey
dc.contributor.authorPerez, Bradford A.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorDaniel, Davey
dc.date.accessioned2021-03-03T11:01:54Z
dc.date.available2021-03-03T11:01:54Z
dc.identifier.citationFaivre-Finn C., Spigel D. R. , Senan S., Langer C., Perez B. A. , ÖZGÜROĞLU M., Daniel D., Villegas A., Vicente D., Hui R., et al., "Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)", LUNG CANCER, cilt.151, ss.30-38, 2021
dc.identifier.issn0169-5002
dc.identifier.othervv_1032021
dc.identifier.otherav_25bb72ab-0813-43e5-adbe-259161420e69
dc.identifier.urihttp://hdl.handle.net/20.500.12627/30250
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2020.11.024
dc.description.abstractIntroduction: The PACIFIC trial demonstrated that durvalumab significantly improved progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III NSCLC and stable or responding disease following concurrent, platinum-based chemoradiotherapy (CRT). A range of CT and RT regimens were permitted, and used, in the trial. We report post-hoc, exploratory analyses of clinical outcomes from PACIFIC according to CRT-related variables.
dc.language.isoeng
dc.subjectOncology
dc.subjectRespiratory Care
dc.subjectPulmonary and Respiratory Medicine
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectSOLUNUM SİSTEMİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.titleImpact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
dc.typeMakale
dc.relation.journalLUNG CANCER
dc.contributor.departmentAstraZeneca , ,
dc.identifier.volume151
dc.identifier.startpage30
dc.identifier.endpage38
dc.contributor.firstauthorID2519095


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record